openPR Logo
Press release

Antifibrinolytic Drugs Market Size, Share, Trends, Global Demand, Growth, Opportunities and Forecast 2022-2027

08-22-2022 03:18 PM CET | Health & Medicine

Press release from: IMARC Group

Antifibrinolytic Drugs Market Size, Share, Trends, Global

The latest research study "Antifibrinolytic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" by IMARC Group, finds that the global antifibrinolytic drugs market reached a value of US$ 15.46 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 20.46 Billion by 2027, exhibiting a CAGR of 4.60% during 2022-2027.

Covid-19 Impact:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Download free sample brochure: https://www.imarcgroup.com/antifibrinolytic-drugs-market/requestsample

Industry Definition and Application:

Antifibrinolytic drugs are medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. They restrict the breakdown of fibrin to treat hemorrhage, coagulation disorders, and vascular tumors. These drugs are also used to control the bleeding during or after intrusive surgeries and manage mucosal bleeding in the nose, gastrointestinal (GI) tract, oropharynx, and uterine-vaginal linings. As a result, antifibrinolytic drugs are widely adopted across clinics, hospitals, and ambulatory surgical centers.

Global Antifibrinolytic Drugs Market Trends and Drivers:

The market is primarily driven by the rising incidence of road accidents, trauma, and several bleeding disorders. In addition, the increasing product adoption to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neuro surgeries represents another major growth-inducing factor. Moreover, the market is further propelled by the growing awareness among the masses regarding the available treatment options for genetic angioedema and hemophilia.

Besides this, various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are accelerating the drug adoption rate. Moreover, other factors, including the rising geriatric population, the introduction of innovative drug variants with improved effectiveness and bio-absorbability, and significant improvements in the healthcare infrastructure, are anticipated to propel market growth in the coming years.

Global Antifibrinolytic Drugs Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/antifibrinolytic-drugs-market

The report has segmented the market on the basis of region, indication, form and end user.

Breakup by Indication:
• Gynecology
• Hereditary Angioedema
• Fibrinolytic Response Testing
• Surgeries
• Others

Breakup by Form:
• Oral
• Injectable

Breakup by End User:
• Hospitals and Clinics
• Ambulatory Surgical Centers
• Trauma Centers
• Others

Breakup by Region:
• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:
• Market Performance (2016-2021)
• Market Outlook (2022- 2027)
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse Other Related Reports by IMARC Group:

Electric Vehicle Range Extender Market Report: https://www.imarcgroup.com/electric-vehicle-range-extender-market

Premise Cable Market Report: https://www.imarcgroup.com/premise-cable-market

Collaborative Robot Market Report: https://www.imarcgroup.com/collaborative-robot-market

Plastic Contract Manufacturing Market Report: https://www.imarcgroup.com/plastic-contract-manufacturing-market

Coffee Pods and Capsules Market Report: https://www.imarcgroup.com/coffee-pods-capsules-market

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antifibrinolytic Drugs Market Size, Share, Trends, Global Demand, Growth, Opportunities and Forecast 2022-2027 here

News-ID: 2712007 • Views:

More Releases from IMARC Group

List of Smartphone Companies in the Worldwide 2024 | IMARC Group
List of Smartphone Companies in the Worldwide 2024 | IMARC Group
A smartphone is a mobile device that allows for increased access to internet-based services and other digital activities. Platforms such as iOS, Android, and Windows Phone support a wide selection of applications built by third-party developers. In terms of hardware, software, and a variety of mobile operating systems, smartphones are a subset of mobile phones distinct from feature phones. Smartphones offer a wide range of services, including music, video, gaming,
Leading E-Pharmacy Companies in the Worldwide 2024 | IMARC Group
Leading E-Pharmacy Companies in the Worldwide 2024 | IMARC Group
E-pharmacy, or electronic pharmacy, is a type of online retail that focuses on the sale and delivery of medicinal items via digital platforms. This strategy enables users to buy drugs and health-related items from any internet-connected device, resulting in ease, accessibility, and competitive cost. E-pharmacies serve people who reside in remote areas or have limited mobility since they reduce the need to visit a pharmacy physically. These platforms follow strict
Top 10 Courier, Express, and Parcel Companies in the World | IMARC Group
Top 10 Courier, Express, and Parcel Companies in the World | IMARC Group
Courier express and parcel companies are investing in advanced tracking systems, route optimization software, and automation technology to enhance efficiency and give real time visibility into parcel movements. They are focusing on reducing transit times through faster transportation methods, such as air freight or same-day delivery options due individual expectations for faster delivery. In addition, they are placing a priority on the user experience by offering user-friendly online platforms for
Top Aquaculture Companies in The World | 2024
Top Aquaculture Companies in The World | 2024
Global Aquaculture Companies Aquaculture is a production system that entails raising different aquatic organisms which include fish, crustaceans, and mollusks. It consists of breeding of freshwater and seawater populations in an environment that can be either a tank, a pool or an enclosed ocean area. It is a dependable and sustainable source of seafood to meet the growing global demand for proteins. It is a significant contributor to food security because

All 5 Releases


More Releases for Antifibrinolytic

Antifibrinolytic Drugs Market: Report Scope and Market Segmentation 2017 - 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025
Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities by 2017 – …
Eosinophilic asthma is a form of asthma categorized by greater levels of eosinophils in the air passages. Eosinophilic asthma includes contraction and inflammation of the air passages that makes breathing very difficult. Various symptoms are observed in eosinophilic asthma. The symptoms of eosinophilic asthma can be treated by many asthma medications like bronchodilators, anti-inflammatories and asthma inhaling systems. Eosinophilic asthma treatment includes: The allergens can be avoided like certain medications ,smoking,
Antifibrinolytic Drugs Market Set to Record Exponential Growth by 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Opportunities and Forecasts, 2017 – 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Foreseen to Grow Exponentially Over 2017 - 2025 : …
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.